The University of Chicago Header Logo

Connection

Nancy Jean Cox to Influenza Vaccines

Back to Details
This is a "connection" page, showing publications Nancy Jean Cox has written about Influenza Vaccines.
Nancy Jean Cox
Connection Strength
5.294
Influenza Vaccines
  1. Global Influenza Surveillance and Response System: 70 years of responding to the expected and preparing for the unexpected. Lancet. 2022 09 24; 400(10357):981-982.
    View in: PubMed
    Score: 0.676
  2. Report on the second WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Geneva, Switzerland, 5-7 May 2014. Vaccine. 2015 Nov 27; 33(48):6503-10.
    View in: PubMed
    Score: 0.418
  3. Seasonal influenza vaccines. Curr Top Microbiol Immunol. 2009; 333:43-82.
    View in: PubMed
    Score: 0.261
  4. Inactivated and live attenuated influenza vaccines in young children--how do they compare? N Engl J Med. 2007 Feb 15; 356(7):729-31.
    View in: PubMed
    Score: 0.229
  5. The total influenza vaccine failure of 1947 revisited: major intrasubtypic antigenic change can explain failure of vaccine in a post-World War II epidemic. Proc Natl Acad Sci U S A. 2002 Aug 06; 99(16):10748-52.
    View in: PubMed
    Score: 0.167
  6. Effectiveness of influenza vaccination of day care children in reducing influenza-related morbidity among household contacts. JAMA. 2000 Oct 04; 284(13):1677-82.
    View in: PubMed
    Score: 0.147
  7. Influenza. Lancet. 1999 Oct 09; 354(9186):1277-82.
    View in: PubMed
    Score: 0.138
  8. A ten-year China-US laboratory collaboration: improving response to influenza threats in China and the world, 2004-2014. BMC Public Health. 2019 May 10; 19(Suppl 3):520.
    View in: PubMed
    Score: 0.134
  9. Kinetics of humoral response in children with acute lymphoblastic leukemia immunized with influenza vaccine in 1993 in Poland. Leuk Lymphoma. 1997 Jun; 26(1-2):163-9.
    View in: PubMed
    Score: 0.117
  10. Improving the selection and development of influenza vaccine viruses - Report of a WHO informal consultation on improving influenza vaccine virus selection, Hong Kong SAR, China, 18-20 November 2015. Vaccine. 2017 02 22; 35(8):1104-1109.
    View in: PubMed
    Score: 0.114
  11. [Vaccination against influenza in children with acute lymphoblastic leukemia]. Pediatr Pol. 1996 Apr; 71(4):301-6.
    View in: PubMed
    Score: 0.108
  12. Development of influenza A(H7N9) candidate vaccine viruses with improved hemagglutinin antigen yield in eggs. Influenza Other Respir Viruses. 2015 Sep; 9(5):263-70.
    View in: PubMed
    Score: 0.104
  13. Strengthening the influenza vaccine virus selection and development process: Report of the 3rd WHO Informal Consultation for Improving Influenza Vaccine Virus Selection held at WHO headquarters, Geneva, Switzerland, 1-3 April 2014. Vaccine. 2015 Aug 26; 33(36):4368-82.
    View in: PubMed
    Score: 0.102
  14. Identification of Influenza A/PR/8/34 Donor Viruses Imparting High Hemagglutinin Yields to Candidate Vaccine Viruses in Eggs. PLoS One. 2015; 10(6):e0128982.
    View in: PubMed
    Score: 0.102
  15. Genetic stability of cold-adapted A/Leningrad/134/47/57 (H2N2) influenza virus: sequence analysis of live cold-adapted reassortant vaccine strains before and after replication in children. J Gen Virol. 1995 Jun; 76 ( Pt 6):1521-5.
    View in: PubMed
    Score: 0.102
  16. Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine. 1995; 13(15):1399-402.
    View in: PubMed
    Score: 0.099
  17. Estimated influenza illnesses and hospitalizations averted by vaccination--United States, 2013-14 influenza season. MMWR Morb Mortal Wkly Rep. 2014 Dec 12; 63(49):1151-4.
    View in: PubMed
    Score: 0.099
  18. Characterization of reverse genetics-derived cold-adapted master donor virus A/Leningrad/134/17/57 (H2N2) and reassortants with H5N1 surface genes in a mouse model. Clin Vaccine Immunol. 2014 May; 21(5):722-31.
    View in: PubMed
    Score: 0.094
  19. WHO recommendations for the viruses used in the 2013-2014 Northern Hemisphere influenza vaccine: Epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from October 2012 to January 2013. Vaccine. 2014 Aug 20; 32(37):4713-25.
    View in: PubMed
    Score: 0.093
  20. Pandemic preparedness and the Influenza Risk Assessment Tool (IRAT). Curr Top Microbiol Immunol. 2014; 385:119-36.
    View in: PubMed
    Score: 0.092
  21. Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia. J Infect Dis. 1993 Oct; 168(4):881-7.
    View in: PubMed
    Score: 0.091
  22. Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010. Influenza Other Respir Viruses. 2013 Sep; 7 Suppl 2:52-53.
    View in: PubMed
    Score: 0.090
  23. WHO recommendations for the viruses to be used in the 2012 Southern Hemisphere Influenza Vaccine: epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from February to September 2011. Vaccine. 2012 Oct 05; 30(45):6461-71.
    View in: PubMed
    Score: 0.084
  24. Comparative immunogenicity and cross-clade protective efficacy of mammalian cell-grown inactivated and live attenuated H5N1 reassortant vaccines in ferrets. J Infect Dis. 2011 Nov 15; 204(10):1491-9.
    View in: PubMed
    Score: 0.079
  25. Genetic bases of the temperature-sensitive phenotype of a master donor virus used in live attenuated influenza vaccines: A/Leningrad/134/17/57 (H2N2). Virology. 2011 Apr 10; 412(2):297-305.
    View in: PubMed
    Score: 0.076
  26. The development of vaccine viruses against pandemic A(H1N1) influenza. Vaccine. 2011 Feb 17; 29(9):1836-43.
    View in: PubMed
    Score: 0.075
  27. Exposure science for viral diseases: 2009 H1N1 pandemic influenza virus. J Expo Sci Environ Epidemiol. 2011 Jan-Feb; 21(1):1-2.
    View in: PubMed
    Score: 0.074
  28. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010 Aug 06; 59(RR-8):1-62.
    View in: PubMed
    Score: 0.073
  29. Development of a new candidate H5N1 avian influenza virus for pre-pandemic vaccine production. Influenza Other Respir Viruses. 2009 Nov; 3(6):287-95.
    View in: PubMed
    Score: 0.069
  30. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med. 2009 Nov 12; 361(20):1945-52.
    View in: PubMed
    Score: 0.068
  31. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep. 2009 Jul 31; 58(RR-8):1-52.
    View in: PubMed
    Score: 0.068
  32. Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses. Arch Intern Med. 2008 Dec 08; 168(22):2405-14.
    View in: PubMed
    Score: 0.065
  33. Anti-ganglioside antibody induction by swine (A/NJ/1976/H1N1) and other influenza vaccines: insights into vaccine-associated Guillain-Barré syndrome. J Infect Dis. 2008 Jul 15; 198(2):226-33.
    View in: PubMed
    Score: 0.063
  34. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR Recomm Rep. 2007 Jul 13; 56(RR-6):1-54.
    View in: PubMed
    Score: 0.059
  35. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children. J Infect Dis. 2006 Oct 15; 194(8):1032-9.
    View in: PubMed
    Score: 0.056
  36. Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006 Jul 28; 55(RR-10):1-42.
    View in: PubMed
    Score: 0.055
  37. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential. Vaccine. 2006 Nov 17; 24(47-48):6859-66.
    View in: PubMed
    Score: 0.055
  38. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2004 May 28; 53(RR-6):1-40.
    View in: PubMed
    Score: 0.047
  39. Genetic stability of A/Ann Arbor/6/60 cold-mutant (temperature-sensitive) live influenza virus genes: analysis by oligonucleotide mapping of recombinant vaccine strains before and after replication in volunteers. J Infect Dis. 1984 Feb; 149(2):194-200.
    View in: PubMed
    Score: 0.046
  40. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2003 Apr 25; 52(RR-8):1-34; quiz CE1-4.
    View in: PubMed
    Score: 0.044
  41. Safety evaluation in chickens of candidate human vaccines against potential pandemic strains of influenza. Avian Dis. 2003; 47(3 Suppl):926-30.
    View in: PubMed
    Score: 0.043
  42. Generation and characterization of an H9N2 cold-adapted reassortant as a vaccine candidate. Avian Dis. 2003; 47(3 Suppl):1127-30.
    View in: PubMed
    Score: 0.043
  43. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2002 Apr 12; 51(RR-3):1-31.
    View in: PubMed
    Score: 0.041
  44. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2001 Apr 20; 50(RR-4):1-44.
    View in: PubMed
    Score: 0.038
  45. Immunogenicity and efficacy of Russian live attenuated and US inactivated influenza vaccines used alone and in combination in nursing home residents. Vaccine. 2000 Sep 15; 19(2-3):308-18.
    View in: PubMed
    Score: 0.037
  46. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000 Apr 14; 49(RR-3):1-38; quiz CE1-7.
    View in: PubMed
    Score: 0.036
  47. Prevention and control of influenza. Lancet. 1999 Dec; 354 Suppl:SIV30.
    View in: PubMed
    Score: 0.035
  48. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis. 1999 Sep-Oct; 5(5):659-71.
    View in: PubMed
    Score: 0.034
  49. Comparative studies of wild-type and cold-mutant (temperature-sensitive) influenza viruses: nonrandom reassortment of genes during preparation of live virus vaccine candidates by recombination at 25 degrees between recent H3N2 and H1N1 epidemic strains and cold-adapted A/An Arbor/6/60. Virology. 1979 Aug; 97(1):190-4.
    View in: PubMed
    Score: 0.034
  50. Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: impact on plasma levels of HIV type 1 RNA and determinants of antibody response. Clin Infect Dis. 1999 Mar; 28(3):541-7.
    View in: PubMed
    Score: 0.033
  51. Influenza pandemic preparedness plan for the United States. J Infect Dis. 1997 Aug; 176 Suppl 1:S4-7.
    View in: PubMed
    Score: 0.030
  52. Selection of antigenically advanced variants of seasonal influenza viruses. Nat Microbiol. 2016 05 23; 1(6):16058.
    View in: PubMed
    Score: 0.027
  53. PCR restriction analysis of genome composition and stability of cold-adapted reassortant live influenza vaccines. J Virol Methods. 1995 Mar; 52(1-2):41-9.
    View in: PubMed
    Score: 0.025
  54. Nonimmunoselected intrastrain genetic variation detected in pairs of high-yielding influenza A (H3N2) vaccine and parental viruses. J Infect Dis. 1994 Dec; 170(6):1432-8.
    View in: PubMed
    Score: 0.025
  55. Influenza activity - United States, 2013-14 season and composition of the 2014-15 influenza vaccines. MMWR Morb Mortal Wkly Rep. 2014 Jun 06; 63(22):483-90.
    View in: PubMed
    Score: 0.024
  56. The global circulation of seasonal influenza A (H3N2) viruses. Science. 2008 Apr 18; 320(5874):340-6.
    View in: PubMed
    Score: 0.016
  57. Comparative studies of wild-type and cold-mutant (temperature-sensitive) influenza virus: detection of mutations in all genes of the A/Ann Arbor/6/60 (H2N2) mutant vaccine donor strain. Microb Pathog. 1986 Aug; 1(4):387-97.
    View in: PubMed
    Score: 0.014
  58. Influenza-associated deaths among children in the United States, 2003-2004. N Engl J Med. 2005 Dec 15; 353(24):2559-67.
    View in: PubMed
    Score: 0.013
  59. A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans. J Virol. 1999 Jul; 73(7):5903-11.
    View in: PubMed
    Score: 0.008
  60. Meeting the challenge of emerging pathogens: the role of the United States Air Force in global influenza surveillance. Mil Med. 1997 Feb; 162(2):82-6.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.